Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | PDE1A | P54750 | 1/20 | 0.42 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.42 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7379340 | 0.94 | CYP3A4 (0.51) | CYP3A4HPGDSMN1; SMN2TDP1ALDH1A1 | |
| SCHEMBL844149 | 0.91 | CYP3A4 (0.49) | CYP3A4HPGDSMN1; SMN2TDP1ALDH1A1 | |
| SCHEMBL6679640 | 0.89 | CYP3A4 (0.50) | CYP3A4HPGDSMN1; SMN2TDP1ALDH1A1 | |
| SCHEMBL15750582 | 0.82 | CYP3A4 (0.44) | CYP3A4HPGDTDP1ALDH1A1MAPT | |
| SCHEMBL28756311 | 0.81 | CYP3A4 (0.51) | CYP3A4HPGDSMN1; SMN2TDP1ALDH1A1 | |
| SCHEMBL11355720 | 0.80 | CYP3A4 (0.47) | CYP3A4HPGDSMN1; SMN2TDP1ALDH1A1 | |
| SCHEMBL11378236 | 0.80 | CYP3A4 (0.47) | CYP3A4HPGDSMN1; SMN2TDP1ALDH1A1 | |
| SCHEMBL844171 | 0.80 | ALDH1A1 (0.50) | CYP3A4HPGDSMN1; SMN2TDP1ALDH1A1 | |
| SCHEMBL11299031 | 0.79 | ALDH1A1 (0.49) | CYP3A4HPGDSMN1; SMN2TDP1ALDH1A1 | |
| SCHEMBL11382105 | 0.78 | ALDH1A1 (0.45) | CYP3A4HPGDSMN1; SMN2TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8552015-B2 | Quinazolinone derivatives and their use as CB agonists | NOVARTIS AG (CH) | 2013-10-08 | — | — | US | disclosed |
| EP-1472234-B1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS CB AGONISTS | NOVARTIS AG (CH) | 2012-03-28 | — | — | EP | disclosed |
| EP-2319839-A1 | Quinazolinone derivatives and their use as CB agonists | Novartis AG (CH) | 2011-05-11 | — | — | EP | disclosed |
| CN-100579968-C | Quinazolinone derivatives and their use as CB agonists | NOVARTIS AG | 2010-01-13 | — | — | CN | disclosed |
| US-20070265285-A1 | Quinazolinone derivatives and their use as CB agonists | NOVARTIS AG (CH) | 2007-11-15 | — | — | US | disclosed |
| CN-1628104-A | Quinazolinone derivatives and their use as CB agonists | NOVARTIS AG (CH) | 2005-06-15 | — | — | CN | disclosed |
| US-20050085493-A1 | Quinazolinone derivatives and their use as cb agonists | BRAIN CHRISTOPHER T (GB) | 2005-04-21 | — | — | US | disclosed |
| EP-1472234-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS CB AGONISTS | Novartis AG (CH) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003066603-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS CB AGONISTS | NOVARTIS AG (CH) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265285-A1 | Quinazolinone derivatives and their use as CB agonists | CNR1, ADRB1, ADRA1D | CYP3A4 91/4885HPGD 910/4885SMN1; SMN2 3618/4885 |
| US-20050085493-A1 | Quinazolinone derivatives and their use as cb agonists | CNR1, ADRB1, ADRA2B | CYP3A4 71/4885HPGD 921/4885SMN1; SMN2 3679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.